Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Lei, Hongxia; Dirren, Elisabeth; Poitry-Yamate, Carole; Schneider, Bernard L; Gruetter, Rolf; Aebischer, Patrick
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 39:Issue 7(2019)
• Page Start: 1283
• Page End: 1298
• Publication Date: 2019-07
• Subjects: Amyotrophic lateral sclerosis -- G93A mutant hSOD1 mouse -- motor neurons -- metabolism -- 1H magnetic resonance spectroscopy; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X18756499
• Languages: English
• ISSNs: 0271-678X

Abstract

In vivo 1 H magnetic resonance spectroscopy ( 1 H-MRS) investigations of amyotrophic lateral sclerosis (ALS) mouse brain may provide neurochemical profiles and alterations in association with ALS disease progression. We aimed to longitudinally follow neurochemical evolutions of striatum, brainstem and motor cortex of mice transgenic for G93A mutant human superoxide dismutase type-1 (G93A-SOD1), an ALS model. Region-specific neurochemical alterations were detected in asymptomatic G93A-SOD1 mice, particularly in lactate (−19%) and glutamate (+8%) of brainstem, along with γ-amino-butyric acid (−30%), N-acetyl-aspartate (−5%) and ascorbate (+51%) of motor cortex. With disease progression towards the end-stage, increased numbers of metabolic changes of G93A-SOD1 mice were observed (e.g. glutamine levels increased in the brainstem (>+66%) and motor cortex (>+54%)). Through ALS disease progression, an overall increase of glutamine/glutamate in G93A-SOD1 mice was observed in the striatum ( p < 0.01) and even more so in two motor neuron enriched regions, the brainstem and motor cortex ( p < 0.0001). These 1 H-MRS data underscore a pattern of neurochemical alterations that are specific to brain regions and to disease stages of the G93A-SOD1 mouse model. These neurochemical changes may contribute to early diagnosis and disease monitoring in ALS patients.